Azenta Reports Q1 2026 Results Amid Operational Challenges
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 03 2026
0mins
Should l Buy AZTA?
Source: seekingalpha
Azenta Inc. shares fell 22.70% as the stock crossed below its 5-day SMA, reflecting investor concerns following the company's Q1 fiscal 2026 financial results.
In its earnings report, Azenta disclosed a revenue of $149 million, a 1% increase year-over-year, but faced a 7% decline from the previous quarter. The diluted EPS from continuing operations was -$0.11, showing an improvement from -$0.16 a year ago, yet the overall losses increased, indicating ongoing financial pressure. Management expressed optimism for the second half of fiscal 2026, despite the challenges.
The mixed results and operational difficulties have raised concerns among investors, leading to a significant drop in the stock price. The company’s strategic initiatives and future outlook will be closely monitored as it navigates through this transformation phase.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AZTA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AZTA
Wall Street analysts forecast AZTA stock price to rise
6 Analyst Rating
4 Buy
2 Hold
0 Sell
Moderate Buy
Current: 22.780
Low
30.00
Averages
39.50
High
45.00
Current: 22.780
Low
30.00
Averages
39.50
High
45.00
About AZTA
Azenta, Inc. is a provider of life sciences solutions worldwide. The Company provides a full suite of cold-chain sample management solutions and multiomics services across areas such as drug development, clinical research and advanced cell therapies for pharmaceutical, biotech, academic and healthcare institutions globally. The Company's segments include Sample Management Solutions and Multiomics. Its Sample Management Solutions segment offers end-to-end sample management products and services, including sample repository services and core products (automated stores, cryogenic systems, automated sample tube, consumables and instruments and controlled rate thawing devices). The Company's Multiomics segment includes its genomic services business, which advances research and development activities by providing gene sequencing, synthesis, editing and related services. The Company's brands include GENEWIZ, FluidX, Ziath, 4titude, Limfinity, Freezer Pro, and Barkey.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Azenta Acquires UK Biocentre to Strengthen Market Position
- Acquisition Overview: Azenta, Inc. announced the acquisition of UK Biocentre for GBP 20.5 million, including up to GBP 1.8 million in contingent consideration, aimed at enhancing its market position in the UK life sciences sector and expected to drive future revenue growth.
- Market Expansion Strategy: This acquisition establishes UK Biocentre as a European operational hub, supporting pharmaceutical, biotechnology, and public health customers, thereby solidifying Azenta's footprint in Europe and enhancing its sample management and processing capabilities.
- Financial Impact Expectations: The acquisition is projected to dilute the 2026 Adjusted EBITDA margin by approximately 35 basis points, but it is expected to positively impact the organic revenue growth rate and EBITDA margin expansion for 2027 and 2028, aligning with the company's long-term growth targets.
- Leadership Outlook: Azenta's CEO John Marotta stated that this acquisition will strengthen the company's sample management solutions platform, enhancing its capabilities in critical workflows within the life sciences ecosystem and driving future innovation and growth.
See More
Azenta Acquires UK Biocentre to Strengthen Market Position
- Acquisition Overview: Azenta, Inc. announced the acquisition of UK Biocentre for GBP 20.5 million, including up to GBP 1.8 million in contingent consideration, aimed at strengthening its market position in the UK life sciences sector and is expected to drive future revenue growth.
- Market Expansion Strategy: The acquisition establishes UK Biocentre as a European operational hub, supporting pharmaceutical, biotechnology, and public health customers, thereby enhancing Azenta's business footprint in Europe and improving its sample management and processing capabilities.
- Financial Impact Expectations: The transaction is anticipated to dilute the adjusted EBITDA margin by approximately 35 basis points in fiscal 2026, but it is expected to positively contribute to organic revenue growth and EBITDA margin expansion in 2027 and 2028, aligning with the company's long-term growth targets.
- Industry Leadership Position: Azenta's CEO John Marotta stated that this acquisition will strengthen its sample management solutions platform, enhancing its capabilities in critical workflows within the life sciences ecosystem, further solidifying the company's leadership position in the global market.
See More
Azenta, Inc. Q1 2026 Earnings Call Insights
- Revenue Performance: Azenta reported total revenue of $149 million for Q1 2026, reflecting a 1% year-over-year increase, yet organic revenue declined by approximately 1%, primarily impacted by a 2% foreign exchange headwind, indicating challenges in the current macroeconomic environment.
- Margin Outlook: Management anticipates an adjusted EBITDA margin expansion of about 300 basis points for 2026, despite the first quarter's EBITDA margin standing at 8.5%, down 230 basis points year-over-year, highlighting underutilized lab capacity in North America and additional costs from automated storage projects.
- Strategic Restructuring: The company confirmed the strategic sale of B Medical expected to close by March 31, alongside a $250 million share repurchase authorization, reflecting a cautious and strategic approach to capital deployment.
- Future Outlook: Azenta reaffirmed its organic revenue growth target of 3% to 5% for fiscal 2026, with expectations for accelerated growth in the second half, particularly as delayed approvals are processed and capital investments ramp up, demonstrating confidence in future market conditions.
See More
Azenta Reports Q1 2026 Earnings with Mixed Results
- Earnings Overview: Azenta's Q1 2026 earnings report reveals a non-GAAP EPS of $0.09, missing expectations by $0.04, while revenue reached $149 million, up 1.4% year-over-year, exceeding forecasts by $1.9 million, indicating resilience in revenue growth.
- Organic Revenue Decline: Despite total revenue growth, organic revenue, excluding foreign exchange impacts, declined by 1% year-over-year, reflecting potential pressures from intensified market competition and demand fluctuations on the company's performance.
- Adjusted EBITDA Performance: The adjusted EBITDA stood at $13 million with an EBITDA margin of 8.5%, down 230 basis points from the previous year, indicating challenges in cost control and operational efficiency that may affect future profitability.
- Future Guidance: The company reiterates its guidance for fiscal year 2026, expecting organic revenue growth in the range of 3% to 5%, with an anticipated EBITDA margin expansion of approximately 300 basis points, demonstrating management's confidence in future growth prospects.
See More
Azenta Reports Q1 Fiscal 2026 Financial Results Amid Discontinued Operations
- Revenue Performance: In Q1 of fiscal 2026, Azenta reported $149 million in revenue from continuing operations, a 7% decline from the previous quarter but a 1% year-over-year increase, indicating slight growth potential amid market challenges.
- Earnings Per Share Shift: The diluted EPS from continuing operations was -$0.11, an improvement from -$0.16 a year ago, despite an overall increase in losses, reflecting financial pressure during the company's transformation phase.
- Adjusted EBITDA Decline: Adjusted EBITDA stood at $13 million, down 39% from the previous quarter, with the EBITDA margin decreasing from 13% to 8.5%, highlighting challenges in cost control and operational efficiency.
- Future Outlook: Management expresses optimism for the second half of fiscal 2026, emphasizing a commitment to sustainable growth through ongoing execution initiatives, despite facing multiple market and operational challenges.
See More
Azenta Reports Q1 Fiscal 2026 Financial Results
- Revenue Performance: In Q1 of fiscal 2026, Azenta reported $149 million in revenue from continuing operations, reflecting a 1% year-over-year increase, but organic revenue declined by 1%, indicating sluggish growth in multiomics and sample management solutions that may impact future market competitiveness.
- Earnings Decline: The diluted EPS from continuing operations was -$0.11, an improvement from -$0.16 a year ago, yet the total diluted EPS fell to -$0.34 from -$0.25, highlighting ongoing challenges in restoring profitability amid operational difficulties.
- Cash Flow and Liquidity: As of December 31, 2025, Azenta had a total cash balance of $571 million and generated $21 million in operating cash flow, with free cash flow at $15 million, necessitating continued focus on capital expenditures and liquidity management to sustain operations.
- Share Repurchase Program: The Board approved a share repurchase program of up to $250 million to be executed by December 31, 2028, aimed at enhancing shareholder value, although no shares have been repurchased to date, reflecting uncertainties in market conditions.
See More
Azenta Acquires UK Biocentre to Strengthen Market Position
- Acquisition Overview: Azenta, Inc. announced the acquisition of UK Biocentre for GBP 20.5 million, including up to GBP 1.8 million in contingent consideration, aimed at enhancing its market position in the UK life sciences sector and expected to drive future revenue growth.
- Market Expansion Strategy: This acquisition establishes UK Biocentre as a European operational hub, supporting pharmaceutical, biotechnology, and public health customers, thereby solidifying Azenta's footprint in Europe and enhancing its sample management and processing capabilities.
- Financial Impact Expectations: The acquisition is projected to dilute the 2026 Adjusted EBITDA margin by approximately 35 basis points, but it is expected to positively impact the organic revenue growth rate and EBITDA margin expansion for 2027 and 2028, aligning with the company's long-term growth targets.
- Leadership Outlook: Azenta's CEO John Marotta stated that this acquisition will strengthen the company's sample management solutions platform, enhancing its capabilities in critical workflows within the life sciences ecosystem and driving future innovation and growth.
See More
Azenta Acquires UK Biocentre to Strengthen Market Position
- Acquisition Overview: Azenta, Inc. announced the acquisition of UK Biocentre for GBP 20.5 million, including up to GBP 1.8 million in contingent consideration, aimed at strengthening its market position in the UK life sciences sector and is expected to drive future revenue growth.
- Market Expansion Strategy: The acquisition establishes UK Biocentre as a European operational hub, supporting pharmaceutical, biotechnology, and public health customers, thereby enhancing Azenta's business footprint in Europe and improving its sample management and processing capabilities.
- Financial Impact Expectations: The transaction is anticipated to dilute the adjusted EBITDA margin by approximately 35 basis points in fiscal 2026, but it is expected to positively contribute to organic revenue growth and EBITDA margin expansion in 2027 and 2028, aligning with the company's long-term growth targets.
- Industry Leadership Position: Azenta's CEO John Marotta stated that this acquisition will strengthen its sample management solutions platform, enhancing its capabilities in critical workflows within the life sciences ecosystem, further solidifying the company's leadership position in the global market.
See More
Azenta, Inc. Q1 2026 Earnings Call Insights
- Revenue Performance: Azenta reported total revenue of $149 million for Q1 2026, reflecting a 1% year-over-year increase, yet organic revenue declined by approximately 1%, primarily impacted by a 2% foreign exchange headwind, indicating challenges in the current macroeconomic environment.
- Margin Outlook: Management anticipates an adjusted EBITDA margin expansion of about 300 basis points for 2026, despite the first quarter's EBITDA margin standing at 8.5%, down 230 basis points year-over-year, highlighting underutilized lab capacity in North America and additional costs from automated storage projects.
- Strategic Restructuring: The company confirmed the strategic sale of B Medical expected to close by March 31, alongside a $250 million share repurchase authorization, reflecting a cautious and strategic approach to capital deployment.
- Future Outlook: Azenta reaffirmed its organic revenue growth target of 3% to 5% for fiscal 2026, with expectations for accelerated growth in the second half, particularly as delayed approvals are processed and capital investments ramp up, demonstrating confidence in future market conditions.
See More
Azenta Reports Q1 2026 Earnings with Mixed Results
- Earnings Overview: Azenta's Q1 2026 earnings report reveals a non-GAAP EPS of $0.09, missing expectations by $0.04, while revenue reached $149 million, up 1.4% year-over-year, exceeding forecasts by $1.9 million, indicating resilience in revenue growth.
- Organic Revenue Decline: Despite total revenue growth, organic revenue, excluding foreign exchange impacts, declined by 1% year-over-year, reflecting potential pressures from intensified market competition and demand fluctuations on the company's performance.
- Adjusted EBITDA Performance: The adjusted EBITDA stood at $13 million with an EBITDA margin of 8.5%, down 230 basis points from the previous year, indicating challenges in cost control and operational efficiency that may affect future profitability.
- Future Guidance: The company reiterates its guidance for fiscal year 2026, expecting organic revenue growth in the range of 3% to 5%, with an anticipated EBITDA margin expansion of approximately 300 basis points, demonstrating management's confidence in future growth prospects.
See More
Azenta Reports Q1 Fiscal 2026 Financial Results Amid Discontinued Operations
- Revenue Performance: In Q1 of fiscal 2026, Azenta reported $149 million in revenue from continuing operations, a 7% decline from the previous quarter but a 1% year-over-year increase, indicating slight growth potential amid market challenges.
- Earnings Per Share Shift: The diluted EPS from continuing operations was -$0.11, an improvement from -$0.16 a year ago, despite an overall increase in losses, reflecting financial pressure during the company's transformation phase.
- Adjusted EBITDA Decline: Adjusted EBITDA stood at $13 million, down 39% from the previous quarter, with the EBITDA margin decreasing from 13% to 8.5%, highlighting challenges in cost control and operational efficiency.
- Future Outlook: Management expresses optimism for the second half of fiscal 2026, emphasizing a commitment to sustainable growth through ongoing execution initiatives, despite facing multiple market and operational challenges.
See More
Azenta Reports Q1 Fiscal 2026 Financial Results
- Revenue Performance: In Q1 of fiscal 2026, Azenta reported $149 million in revenue from continuing operations, reflecting a 1% year-over-year increase, but organic revenue declined by 1%, indicating sluggish growth in multiomics and sample management solutions that may impact future market competitiveness.
- Earnings Decline: The diluted EPS from continuing operations was -$0.11, an improvement from -$0.16 a year ago, yet the total diluted EPS fell to -$0.34 from -$0.25, highlighting ongoing challenges in restoring profitability amid operational difficulties.
- Cash Flow and Liquidity: As of December 31, 2025, Azenta had a total cash balance of $571 million and generated $21 million in operating cash flow, with free cash flow at $15 million, necessitating continued focus on capital expenditures and liquidity management to sustain operations.
- Share Repurchase Program: The Board approved a share repurchase program of up to $250 million to be executed by December 31, 2028, aimed at enhancing shareholder value, although no shares have been repurchased to date, reflecting uncertainties in market conditions.
See More
